Associate Director
Arrowhead Pharmaceuticals
Associate Director
Arrowhead Pharmaceuticals
Develops RNAi-based gene-silencing therapies
Arrowhead Pharmaceuticals, Inc. (Nasdaq ARWR) is a commercial stage biopharmaceutical company that develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The depth and versatility of our RNAi technologies enables us to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologics. Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver and lung with a promising pipeline of preclinical candidates.
Arrowhead’s corporate headquarters is in Pasadena, CA with research and development teams in Madison, WI & San Diego, CA, and a state of the art manufacturing facility in Verona, WI. Our employees are nimble, science-driven innovators who are collaborating to bring new therapies to patients in need.
The Position
The Associate Director, External Manufacturing will serve as Arrowhead's primary technical and operational owner for a focused portfolio of 1–3 strategic Contract Development and Manufacturing Organizations (CDMOs) supporting the manufacture of siRNA-based therapeutics. This individual will be accountable for end-to-end CDMO relationship management, technology transfer, GMP supply, and lifecycle performance for drug substance (oligonucleotide synthesis and conjugation), targeted delivery components (e.g., GalNAc and other ligand systems), and/or drug product manufacturing operations.
Operating as the single point of accountability for assigned CDMO partners, this leader will work seamlessly across Process Development, Analytical Development, Quality, Regulatory, Supply Chain, Program Management, and Clinical Operations to ensure robust, compliant, predictable, and cost-effective supply of clinical and commercial product. The successful candidate is, above all, a highly effective cross-functional leader — someone who builds trust quickly, drives alignment among diverse stakeholders, and converts technical complexity into clear decisions and forward momentum.
This role plays a critical part in scaling Arrowhead's platform-enabled RNAi candidates from development through late-stage clinical and commercial readiness, while supporting global regulatory filings and inspection readiness.
This position is approved at the Associate Director level. Candidates with significantly greater depth of relevant experience, demonstrated leadership of complex external manufacturing programs, and a track record of successfully managing late-stage or commercial CDMO partnerships may be considered at the Director level. Final leveling will be based on experience and qualifications.
This role is based in onsite with an expectation to be in the office five days a week.
Responsibilities
CDMO Ownership & External Manufacturing Leadership (1–3 Key Partners)
Cross-Functional Leadership (Core Competency)
Platform-Based CMC & Technical Oversight
Clinical-to-Commercial Readiness
Regulatory & Quality Interface
Requirements
Preferred
Arrowhead provides competitive salaries and an excellent benefit package.
Candidates must have current, valid authorization to work in the country where this role is located.
Wisconsin pay range 150000 - 170000 USD
Develops RNAi-based gene-silencing therapies
Arrowhead Pharmaceuticals develops medicines using RNA interference (RNAi) to silence disease-causing genes. The company’s approach uses a library of RNA chemistries and delivery methods to trigger RNAi, enabling rapid and durable reduction of target gene expression in cells. This gene-silencing strategy aims to treat severe genetic diseases such as cystic fibrosis and hepatitis B by lowering disease-related proteins. Arrowhead’s products are advanced through discovery and development partnerships, licensing deals, and potential commercialization of approved therapies. The company differentiates itself through a broad RNAi platform, proprietary delivery tech, and collaborations with larger pharma firms to advance its pipeline. Its goal is to provide new treatment options for conditions with limited or no effective therapies by translating gene silencing into medicines that can halt or reverse disease progression.
Explore more opportunities at Arrowhead Pharmaceuticals